StockNews.com Initiates Coverage on Taro Pharmaceutical Industries (NYSE:TARO)

Equities research analysts at StockNews.com assumed coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO) in a research report issued to clients and investors on Sunday. The brokerage set a “strong-buy” rating on the stock.

Taro Pharmaceutical Industries Price Performance

Taro Pharmaceutical Industries stock opened at $42.97 on Friday. The firm has a market capitalization of $1.62 billion, a PE ratio of 29.84 and a beta of 0.56. The company’s 50-day moving average is $42.61 and its 200-day moving average is $42.26. Taro Pharmaceutical Industries has a fifty-two week low of $32.67 and a fifty-two week high of $45.76.

Taro Pharmaceutical Industries (NYSE:TARO) last announced its quarterly earnings results on Monday, May 20th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.12. Taro Pharmaceutical Industries had a net margin of 8.56% and a return on equity of 3.75%. The business had revenue of $164.94 million for the quarter, compared to analyst estimates of $156.10 million.

Institutional Trading of Taro Pharmaceutical Industries

Institutional investors have recently bought and sold shares of the business. Crystalline Management Inc. bought a new stake in shares of Taro Pharmaceutical Industries during the 4th quarter worth approximately $297,000. Strs Ohio lifted its holdings in shares of Taro Pharmaceutical Industries by 385.2% during the 4th quarter. Strs Ohio now owns 13,100 shares of the company’s stock worth $547,000 after acquiring an additional 10,400 shares during the period. SG Americas Securities LLC lifted its holdings in shares of Taro Pharmaceutical Industries by 24.5% during the 4th quarter. SG Americas Securities LLC now owns 4,673 shares of the company’s stock worth $195,000 after acquiring an additional 921 shares during the period. FNY Investment Advisers LLC bought a new stake in shares of Taro Pharmaceutical Industries during the 4th quarter worth approximately $105,000. Finally, PenderFund Capital Management Ltd. bought a new stake in shares of Taro Pharmaceutical Industries during the 4th quarter worth approximately $92,000. Institutional investors own 91.40% of the company’s stock.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.